Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 8:8:1902.
doi: 10.3389/fimmu.2017.01902. eCollection 2017.

Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis

Rebecca A Marsh  1
Affiliations
Review

Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis

Rebecca A Marsh. Front Immunol. .

Abstract

Epstein-Barr virus (EBV) is a ubiquitous virus that infects nearly all people worldwide without serious sequela. However, for patients who have genetic diseases which predispose them to the development of hemophagocytic lymphohistiocytosis (HLH), EBV infection is a life-threatening problem. As a part of a themed collection of articles on EBV infection and human primary immune deficiencies, we will review key concepts related to the understanding and treatment of HLH.

Keywords: Epstein–Barr virus; Mononucleosis; X-linked Lymphoproliferative Disease; hemophagocytic lymphohistiocytosis; primary immunodeficiency.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of involvement of selected primary hemophagocytic lymphohistiocytosis proteins in cytotoxic lymphocyte degranulation and target cell killing. Antibodies against markers used in selected screening diagnostics are also shown (perforin and CD107a).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 4(10):757–68.10.1038/nrc1452 - DOI - PubMed
    1. Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood (2010) 116(26):5824–31.10.1182/blood-2010-04-282392 - DOI - PubMed
    1. Xu XJ, Wang HS, Ju XL, Xiao PF, Xiao Y, Xue HM, et al. Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study. Pediatr Blood Cancer (2017) 64(4).10.1002/pbc.26264 - DOI - PubMed
    1. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 20(2):129–35.10.1038/2424 - DOI - PubMed
    1. Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 395(6701):462–9.10.1038/26683 - DOI - PubMed
-